(Toronto, June 1, 2026) JMIR Publications today released a News and Perspectives report on emerging pharmaceutical access models in the United States. In " Affordable GLP-1? When Digital Platforms Meet Policy Reform ", JMIR Correspondent Xiangming Jenny Zhan investigates how a convergence of federal policy, manufacturer-led digital distribution, and telehealth integration has drastically lowered the cost of GLP-1 medications outside the traditional insurance system.
Shifting Access
Up until recently, GLP-1 medications like semaglutide and tirzepatide remained largely out of reach for patients without generous insurance coverage, costing upwards of $1000 to $1349 USD per month, reports Zhan. However, in early 2026, prices dropped below $350 USD due to three distinct forces: federal Most-Favored-Nation pricing deals, the launch of direct-to-consumer platforms by pharmaceutical manufacturers like Novo Nordisk and Eli Lilly, and the integration of GLP-1 prescribing into telehealth startups and mainstream retail. These forces culminated in the launch of TrumpRx.gov, a federal platform connecting cash-paying patients to reduced medication prices.
The Continuity Problem
While lower prices have expanded access, sustaining treatment remains a significant challenge. Because this new cash-pay model operates entirely outside the insurance system, purchases do not count toward deductibles or out-of-pocket maximums, leaving patients who need indefinite treatment without financial protection. Furthermore, the foundation of some direct-to-consumer platforms remains uncertain, as leading telehealth providers face FDA shipping restrictions and patent infringement lawsuits over lower-cost compounded GLP-1 products.
Broader Implications
Though continuity remains an issue, this access model has the potential to expand beyond GLP-1s to other chronic condition treatments, including $25 monthly insulin and heavily discounted COPD inhalers—potentially reshaping how Americans access treatment. "GLP-1s are, in effect, a test case for whether a viable access pathway for chronic disease medications can be sustained outside the insurance system," Zhan writes. Ultimately, the long-term success of this model will depend on whether this digital infrastructure can support continuous care.
Please cite as:
Zhan XJ. Affordable GLP-1? When Digital Platforms Meet Policy Reform.
J Med Internet Res 2026;28:e101366
URL: https://www.jmir.org/2026/1/e102069
DOI: 10.2196/102069
About JMIR Publications News and Perspectives
JMIR Publications is a leading open access publisher of digital health research. The News and Perspectives section is the newest addition to its portfolio, established to bring the rigor and integrity of academic publishing to scientific journalism. The section features well-researched, expert-driven content from the Scientific News Editor, Kayleigh-Ann Clegg, PhD, and a network of specialist JMIR Publications Correspondents to keep the digital health community informed, inspired, and ahead of the curve.
About JMIR Publications
JMIR Publications is a leading open access publisher of digital health research and a champion of open science. With a focus on author advocacy and research amplification, JMIR Publications partners with researchers to advance their careers and maximize the impact of their work. As a technology organization with publishing at its core, we provide innovative tools and resources that go beyond traditional publishing, supporting researchers at every step of the dissemination process. Our portfolio features a range of peer-reviewed journals, including the renowned Journal of Medical Internet Research.
To find out more about JMIR Publications, visit jmirpublications.com or connect with them on Bluesky , X
